Elevation of Plasma Homocysteine and Minor Hallucinations in Parkinson’s Disease: A Cross-Sectional Study

Table 5

Correlations between Hcy and clinical parameters.

Variable
Age	0.125	0.480
LEDD	0.148	0.405
UPDRS III	0.354	0.040
NMS-Quest	0.371	0.031
Gastrointestinal tract	0.408	0.016
Urinary tract	0.236	0.179
Sexual function	-0.107	0.545
Cardiovascular	0.444	0.008
Apathy/attention/memory	0.306	0.078
Depression/anxiety/anhedonia	-0.078	0.660
Sleep/fatigue	0.38	0.027
Pain (unrelated to other causes)	-0.225	0.200
Miscellaneous (e.g., diplopia and weight loss)	0.021	0.907
PDSS	-0.212	0.229
MoCA	-0.103	0.563
Visuospatial/executive	-0.361	0.036
Naming	/	/
Attention	0.165	0.351
Language	-0.284	0.104
Abstraction	0.259	0.139
Delayed memory	0.08	0.651
Orientation	-0.009	0.960
HAMA	-0.02	0.912
HAMD	0.074	0.679
PDQ39	0.287	0.100
Folate	-0.476	0.004
VB12	-0.417	0.014

Significant results are highlighted in bold (). The scores were calculated from the NMS-Quest total score excluding the hallucination/delusion domain score. : Spearman’s rank correlation coefficient; LEDD: Levodopa equivalent daily dose; UPDRS III: the Unified Parkinson’s Disease Rating Scale part III; NMS-Quest: Non-Motor Symptoms Questionnaire; PDSS: The PD Sleep Scale; MOCA: Montreal Cognitive Assessment; HAMA: Hamilton Anxiety Rating Scale; HAMD: Hamilton Depression Rating Scale. PDQ39: Parkinson’s Disease Questionnaire-39; VB12: vitamin B12.